In Brief: An Expanded Indication for Enhertu
The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 87-87
DOI: 10.58347/tml.2026.1755d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026.
Abstract (Originalsprache)
Fam-trastuzumab deruxtecan (Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or metastatic breast cancer. The drug was approved earlier for use as monotherapy in adults with previously treated HER2-positive unresectable or metastatic breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: An Expanded Indication for Enhertu. The Medical Letter on Drugs and Therapeutics, 68(1755), 87-87. https://doi.org/10.58347/tml.2026.1755d
Vancouver
In Brief: An Expanded Indication for Enhertu. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):87-87. doi:10.58347/tml.2026.1755d
BibTeX
@article{euvimed2026,
title = {In Brief: An Expanded Indication for Enhertu},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1755},
pages = {87--87},
doi = {10.58347/tml.2026.1755d}
}
EUVIMED